Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Brugge – page 21

1 245 clinical trials in Brugge, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Brugge at a glance
1 245
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 245 trials in Brugge

Open in trial search

Asthma

Recruiting

Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Prednisolone Acetate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Basilea Pharmaceutica International AG Allschwil

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Debiopharm International S.A.

Neoplasm

Recruiting

Study of BMS-986482 alone or with nivolumab, relatlimab or bevacizumab in patients with advanced solid tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:AAV-ABCA4-Int-C
  • Sponsor:Splicebio S.L.

Evaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Brugge

What the registry says about research in the country

01 Bacterial Infections and Mycoses

Researchers in Brugge are advancing prevention and treatment of bacterial infections and fungal diseases through vaccine and antimicrobial studies.

  • Pneumococcal conjugate vaccine efficacy in infants
  • New antimicrobial agents for resistant bacterial strains
  • Diagnostic tools for invasive fungal infections
  • Safety assessment of novel antifungal prophylaxis

These trials aim to strengthen protection against serious infections and support public health in the region.

02 Cardiovascular Diseases

Investigators are testing innovative therapies to lower heart risk in patients with atherosclerosis, elevated lipoprotein(a), and amyloid‑related cardiomyopathy.

  • GLP‑1 analogue for ASCVD outcomes
  • Lipoprotein(a)‑lowering agent pelacarsen
  • RNA‑based therapy NTLA‑2001 for ATTR cardiomyopathy
  • Muvalaplin to reduce major cardiovascular events

The goal is to reduce morbidity and mortality from heart disease, a leading health concern in Brugge.

03 Digestive System Diseases

Studies target gastrointestinal disorders, evaluating novel compounds for irritable bowel syndrome relief and ulcerative colitis remission.

  • Comparative trial of ebastine vs mebeverine for IBS
  • Obefazimod for endoscopic improvement in ulcerative colitis
  • Long‑term safety of ABX464 in ulcerative colitis
  • Patient‑reported outcomes for bowel symptom management

Advances aim to enhance quality of life for individuals living with chronic digestive conditions.

04 Hemic and Lymphatic Diseases

A range of trials on hematologic malignancies are underway, seeking more effective regimens for lymphomas and acute leukemias.

  • Epcoritamab added to R‑mini‑CHOP for DLBCL
  • Lacutamab combined with GemOx in peripheral T‑cell lymphoma
  • Ziftomenib plus standard chemotherapy for NPM1‑mutated AML
  • Targeted therapy for KMT2A‑rearranged AML

These efforts aim to improve survival and reduce treatment toxicity for patients with blood cancers in the city.

05 Immune System Diseases

Research includes autoimmune and immune‑mediated conditions, testing agents that restore immune balance such as in chronic graft‑versus‑host disease and Graves’ disease.

  • Belumosudil versus best available therapy for chronic GVHD
  • IMVT‑1402 for maintaining euthyroidism in Graves’ disease
  • Immunogenicity study of PCV21 versus 15vPCV in infants
  • Novel immunomodulators for rare immune disorders

Outcomes may provide new options for patients whose immune systems attack their own tissues.

06 Male Urogenital Diseases

Trials focus on advanced prostate cancer, comparing targeted agents with standard chemotherapy to extend survival in metastatic castration‑resistant prostate cancer.

  • BNT324 versus docetaxel in mCRPC
  • Pasritamig combined with best supportive care for late‑line mCRPC
  • Biomarker‑driven therapy for hormone‑refractory prostate tumors
  • Quality‑of‑life assessments in prostate cancer treatment

The aim is to offer men in Brugge more effective therapeutic choices when disease progresses.

07 Neoplasms

Broad oncology programs explore innovative treatments for ovarian cancer and other gynecologic malignancies, including fallopian tube and peritoneal tumors.

  • Sofetabart Mipitecan with/without bevacizumab for platinum‑resistant ovarian cancer
  • Combination strategies for platinum‑sensitive ovarian disease
  • Targeted maintenance therapies after surgery
  • Translational studies linking tumor genetics to response

These studies strive to improve response rates and long‑term outcomes for women affected by gynecologic malignancies in Brugge.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.